Sherr JL, Heinemann L, Fleming GA, Bergenstal RM, Bruttomesso D, Hanaire H, Holl RW, Petrie JR, Peters AL, Evans M (2022) Automated insulin delivery: benefits, challenges, and recommendations. A consensus report of the joint diabetes technology working group of the European association for the study of diabetes and the American diabetes association. Diabetes Care 45:3058–3074

Article  CAS  PubMed  Google Scholar 

Pettus JH, Kushner JA, Valentine V, Wood R, Pang C, Paranjape S, Berria R, Deluzio A, Edelman SE (2019) Adjunct therapy in type 1 diabetes: A survey to uncover unmet needs and patient preferences beyond HbA1c measures. Diabetes Technol Ther 21:336–343

Article  PubMed Central  PubMed  Google Scholar 

Timmons JG, Littlejohn L, Boyle JG, Petrie JR (2022) Recent developments in adjunct therapies for type 1 diabetes. Expert Opin Investig Drugs 31:1311–1320

Article  CAS  PubMed  Google Scholar 

Fioretto P, Giaccari A, Sesti G (2015) Efficacy and safety of Dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus. Cardiovasc Diabetol 14:142

Article  PubMed Central  PubMed  Google Scholar 

Phillip M, Mathieu C, Lind M, Araki E, di Bartolo P, Bergenstal R, Heller S, Hansen L, Scheerer MF, Thoren F, Arya N, Xu J, Iqbal N, Dandona P (2021) Long-term efficacy and safety of Dapagliflozin in patients with inadequately controlled type 1 diabetes: pooled 52-week outcomes from the DEPICT-1 and– 2 studies. Diabetes Obes Metab 23:549–560

Article  CAS  PubMed  Google Scholar 

European Medicines Agenxy (2019) First oral add-on treatment to insulin for treatment of certain patients with type 1 diabetes. https://www.emaeuropaeu/en/news/first-oral-add-treatment-insulin-treatment-certain-patients-type-1-diabetes

Rosenstock J, Marquard J, Laffel LM, Neubacher D, Kaspers S, Cherney DZ, Zinman B, Skyler JS, George J, Soleymanlou N, Perkins BA (2018) Empagliflozin as adjunctive to insulin therapy in type 1 diabetes: the EASE trials. Diabetes Care 41:2560–2569

Article  CAS  PubMed  Google Scholar 

Wolfsdorf JI, Ratner RE (2019) SGLT inhibitors for type 1 diabetes: proceed with extreme caution. Diabetes Care 42:991–993

Article  CAS  PubMed  Google Scholar 

Hussain S, Nathan H, Rowles S (2022) Dapagliflozin use in type 1 diabetes: industry, business and ethics. Brit J Diabetes;22

Baechle C, Rosenbauer J, Stahl-Pehe A, Seufert J, Mader JK, Wagner C, Wosch FJ, Erath D, Holl RW, Lanzinger S (2025) Effectiveness of add-on therapy with SGLT2 inhibitors or GLP-1 receptor agonists in adults with type 1 diabetes: A prospective DPV registry study. Diabetes Obes Metab 27:1591–1596

Article  CAS  PubMed  Google Scholar 

Bayona Cebada A, Nattero-Chavez L, Alonso Diaz S, Escobar-Morreale HF, Luque-Ramirez M (2020) Efficacy and safety of SGLT2 inhibitors in type 1 diabetes after the introduction of an Off-Label use protocol for clinical practice. Diabetes Technol Ther 22:208–215

Article  CAS  PubMed  Google Scholar 

Duran-Martinez M, Azriel S, Doulatram-Gamgaram VK, Moreno-Perez O, Pines-Corrales PJ, Tejera-Perez C, Merino-Torres JF, Brito-Sanfiel M, Chico A, Marco A, Garcia-Fernandez E, Martinez-Montoro JI (2024) Real-world safety and effectiveness of Dapagliflozin in people living with type 1 diabetes in Spain: the Dapa-ON multicenter retrospective study. Diabetes Metab 50:101501

Article  CAS  PubMed  Google Scholar 

Edwards K, Li X, Lingvay I (2023) Clinical and safety outcomes with GLP-1 receptor agonists and SGLT2 inhibitors in type 1 diabetes: A Real-World study. J Clin Endocrinol Metab 108:920–930

Article  PubMed  Google Scholar 

El Hage L, Kashyap SR, Rao P (2019) Use of SGLT-2 inhibitors in patients with type 1 diabetes mellitus. J Prim Care Community Health 10:2150132719895188

Article  PubMed  Google Scholar 

Fallatah W, Brema I, Alobedallah A, Alkhathami R, Zaheer S, AlMalki E, Almehthel M, Alzahrani S, AlMalki MH (2022) Efficacy and safety of SGLT2 inhibitors as adjunctive treatment in type 1 diabetes in a tertiary care center in Saudi Arabia. Avicenna J Med 12:10–15

Article  PubMed Central  PubMed  Google Scholar 

Hampp C, Swain RS, Horgan C, Dee E, Qiang Y, Dutcher SK, Petrone A, Chen Tilney R, Maro JC, Panozzo CA (2020) Use of Sodium-Glucose cotransporter 2 inhibitors in patients with type 1 diabetes and rates of diabetic ketoacidosis. Diabetes Care 43:90–97

Article  CAS  PubMed  Google Scholar 

Hironaka J, Okada H, Hamaguchi M, Sakai K, Minamida M, Kondo Y, Hashimoto Y, Kitagawa N, Yano M, Yamazaki M, Hasegawa G, Horiguchi G, Teramukai S, Fukui M (2023) Effects of Dapagliflozin on renal function in type 1 diabetes patients in the real world: A retrospective multicenter study of the KAMOGAWA-A cohort. Diabetes Res Clin Pract 202:110794

Article  CAS  PubMed  Google Scholar 

Horii T, Oikawa Y, Atsuda K, Shimada A (2021) On-label use of sodium-glucose cotransporter 2 inhibitors might increase the risk of diabetic ketoacidosis in patients with type 1 diabetes. J Diabetes Investig 12:1586–1593

Article  PubMed Central  CAS  PubMed  Google Scholar 

Palanca A, van Nes F, Pardo F, Ampudia Blasco FJ, Mathieu C (2022) Real-world evidence of efficacy and safety of SGLT2 inhibitors as adjunctive therapy in adults with type 1 diabetes: A European Two-Center experience. Diabetes Care 45:650–658

Article  CAS  PubMed  Google Scholar 

Raj A, Bansiya V, Evans ML, Boughton CK (2022) Implementation of Dapagliflozin as adjunctive therapy in type 1 diabetes: A single centre real-world experience. Diabet Med 39:e14764

Article  CAS  PubMed  Google Scholar 

Shimoda M, Mashiko A, Katakura Y, Sanada J, Fushimi Y, Obata A, Kimura T, Kohara K, Tatsumi F, Nakanishi S, Mune T, Kaku K, Kaneto H (2021) Efficacy and safety of adding Ipragliflozin to insulin in Japanese patients with type 1 diabetes mellitus: a retrospective study. Endocr J 68:1455–1461

Article  CAS  PubMed  Google Scholar 

Silva VB, Fonseca L, Duarte DB, Puga FM, Assuncao G, Garrido S, Teixeira S, Vilaverde J, Cardoso MH (2023) Efficacy and safety of SGLT2 inhibitors in individuals with type 1 diabetes under continuous subcutaneous insulin infusion: a real-world study. Endocr Regul 57:144–151

Article  PubMed  Google Scholar 

Stougaard EB, Kristensen PL, Kielgast U, Andersen HU, Hamid Y, Gaede PH, Sondergaard E, Dorflinger GH, Fjeldborg KK, Hansen KW, Thomsen HH, Al-Imar TMJ, Roder M, Sridhar VS, Cherney D, Rossing P, Persson F (2022) Real life evaluation of sodium-glucose cotransporter 2 Inhibition in type 1 diabetes and the risk of diabetic ketoacidosis. Diab Vasc Dis Res 19:14791641221130043

Article  PubMed Central  CAS  PubMed  Google Scholar 

Suzuki D, Yamada H, Yoshida M, Funazaki S, Amamoto M, Morimoto J, Hara K (2020) Sodium-glucose cotransporter 2 inhibitors improved time-in-range without increasing hypoglycemia in Japanese patients with type 1 diabetes: A retrospective, single-center, pilot study. J Diabetes Investig 11:1230–1237

Article  PubMed Central  CAS  PubMed  Google Scholar 

Jendle JH, Ampudia-Blasco FJ, Fuchtenbusch M, Pozzilli P (2021) Dapagliflozin as an adjunct therapy to insulin in patients with type 1 diabetes mellitus: efficacy and safety of this combination. TouchREV Endocrinol 17:12–20

Article  PubMed Central  PubMed  Google Scholar 

Lunati ME, Cimino V, Gandolfi A, Trevisan M, Montefusco L, Pastore I, Pace C, Betella N, Favacchio G, Bulgheroni M, Bucciarelli L, Massari G, Mascardi C, Girelli A, Morpurgo PS, Folli F, Luzi L, Mirani M, Pintaudi B, Bertuzzi F, Berra C, Fiorina P (2022) SGLT2-inhibitors are effective and safe in the elderly: the SOLD study. Pharmacol Res 183:106396

Article  CAS  PubMed  Google Scholar 

Bonora BM, Avogaro A, Fadini GP (2018) Sodium-glucose co-transporter-2 inhibitors and diabetic ketoacidosis: an updated review of the literature. Diabetes Obes Metab 20:25–33

Article  CAS  PubMed  Google Scholar 

Martinez-Montoro JI, Picon-Cesar MJ, Simon-Frapolli VJ, Pinzon-Martin JL, Garcia-Aleman J, Duran-Martinez M, Tinahones FJ (2023) Evaluation of the clinical impact of Dapagliflozin discontinuation as adjunctive therapy for patients with type 1 diabetes after indication withdrawal: A Two-Center retrospective study. Diabetes Care 46:e101–e102

Article  PubMed Central  CAS  PubMed  Google Scholar 

Groop PH, Dandona P, Phillip M, Gillard P, Edelman S, Jendle J, Xu J, Scheerer MF, Thoren F, Iqbal N, Repetto E, Mathieu C (2020) Effect of Dapagliflozin as an adjunct to insulin over 52 weeks in individuals with type 1 diabetes: post-hoc renal analysis of the DEPICT randomised controlled trials. Lancet Diabetes Endocrinol 8:845–854

Article  CAS  PubMed  Google Scholar 

Sridhar VS, Heerspink HJL, Davies MJ, Banks P, Girard M, Garg SK, Cherney DZI (2023) The effects of Sotagliflozin in type 1 diabetes on clinical markers associated with cardiorenal protection: an exploratory analysis of inTandem3. Diabetes Care 46:e133–e135